Levamisole for children with nephrotic syndrome: new evidence for the use of an "old" drug
- PMID: 30606425
- DOI: 10.1016/j.kint.2018.10.008
Levamisole for children with nephrotic syndrome: new evidence for the use of an "old" drug
Abstract
In the current issue of Kidney International, Sinha et al. report results of a randomized controlled trial comparing levamisole and mycophenolate mofetil for the second-line treatment of children with frequent relapses of nephrotic syndrome. This study suggests that these two agents may both be safe and effective. The present commentary addresses strengths and limitations of this important study.
Copyright © 2018 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
Comment on
-
Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial.Kidney Int. 2019 Jan;95(1):210-218. doi: 10.1016/j.kint.2018.08.039. Epub 2018 Nov 26. Kidney Int. 2019. PMID: 30497684 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
